Rate and Amplification of Drug Resistance among Previously‐Treated Patients with Tuberculosis in Kampala, Uganda
Open Access
- 1 November 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (9), 1126-1134
- https://doi.org/10.1086/592252
Abstract
Background. Drug-resistant Mycobacterium tuberculosis has emerged as a global threat. In resource-constrained settings, patients with a history of tuberculosis (TB) treatment may have drug-resistant disease and may experience poor outcomes. There is a need to measure the extent of and risk factors for drug resistance in such patients. Methods. From July 2003 through November 2006, we enrolled 410 previously treated patients with TB in Kampala, Uganda. We measured the prevalence of resistance to first- and second-line drugs and analyzed risk factors associated with baseline and acquired drug resistance. Results. The prevalence of multidrug-resistant TB was 12.7% (95% confidence interval [95% CI], 9.6%–16.3%). Resistance to second-line drugs was low. Factors associated with multidrug-resistant TB at enrollment included a history of treatment failure (odds ratio, 23.6; 95% CI, 7.7–72.4), multiple previous TB episodes (odds ratio, 15.6; 95% CI, 5.0–49.1), and cavities present on chest radiograph (odds ratio, 5.9; 95% CI, 1.2–29.5). Among a cohort of 250 patients, 5.2% (95% CI, 2.8%–8.7%) were infected with M. tuberculosis that developed additional drug resistance. Amplification of drug resistance was associated with existing drug resistance at baseline (P×.01) and delayed sputum culture conversion (P×.01). Conclusions. The burden of drug resistance in previously treated patients with TB in Uganda is sizeable, and the risk of generating additional drug resistance is significant. There is an urgent need to improve the treatment for such patients in low-income countries.This publication has 35 references indexed in Scilit:
- Evidence of ‘amplifier effect’ in pulmonary multidrug-resistant tuberculosis: report of three casesInternational Journal of Infectious Diseases, 2007
- Risk of Acquired Drug Resistance during Short-Course Directly Observed Treatment of Tuberculosis in an Area with High Levels of Drug ResistanceClinical Infectious Diseases, 2007
- M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV- infected and non-HIV-infected patients in northern TanzaniaBMC Microbiology, 2007
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- The Effect of Initial Drug Resistance on Treatment Response and Acquired Drug Resistance during Standardized Short-Course Chemotherapy for TuberculosisClinical Infectious Diseases, 2004
- Mycobacterium tuberculosisGrowth at theCavity Surface: a Microenvironment with FailedImmunityInfection and Immunity, 2003
- Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus"BMJ, 1998
- Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospitalArchives of Internal Medicine, 1994
- Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, ZambiaTubercle and Lung Disease, 1993